ViiV Receives EU Authorization for Juluca, the First 2-Drug, Once-Daily Pill for HIV

ViiV Receives EU Authorization for Juluca, the First 2-Drug, Once-Daily Pill for HIV

Source: 
CP Wire
snippet: 

ViiV Healthcare, announced on 5/21/18  that the European Commission has granted marketing authorisation for Juluca (dolutegravir 50mg/rilpivirine 25mg) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.